Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOHAMMED M MILHEM

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1558429100
CMS profile
806076
Location
IOWA CITY, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$53.18

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $53.18 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $53.18 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOHAMMED M MILHEM

NPI 1558429100 · CMS profile ID 806076

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

IOWA CITY, IA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOHAMMED M MILHEM, NPI 1558429100, CMS profile ID 806076. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MOHAMMED M MILHEM, NPI 1558429100, CMS profile ID 806076. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MOHAMMED M MILHEM, NPI 1558429100, CMS profile ID 806076, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1558429100?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $53.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $53.1804/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1242511626 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,538.13 7
PY2021 $18.12 2
PY2022 $21.70 2
PY2025 $53.18 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $9,472.81 4
PY2025 Principal investigator $581,246.58 77
PY2024 Principal investigator $999,952.01 109
PY2023 Recipient $1,270.00 2
PY2023 Principal investigator $827,610.63 137
PY2022 Principal investigator $1,233,503.31 110
PY2021 Principal investigator $751,345.38 31
PY2020 Principal investigator $896,218.13 99
PY2019 Recipient $476.00 1
PY2019 Principal investigator $1,105,673.41 103

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

81 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $11,443.75 12/31/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 1232926331
Principal investigator 1 Merck Sharp & Dohme LLC $24,228.40 11/17/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma# A Randomized, Double-blind Phase III Study KEYNOTE 716 No dispute reported 06/30/2026 1232926329
Principal investigator 1 Deciphera Pharmaceuticals Inc. $22,456.00 10/28/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A STUDY OF DCC-2618 VS SUNITINIB IN ADVANCED GIST PATIENTS AFTER TREATMENT WITH IMATINIB (INTRIGUE) No dispute reported 06/30/2026 1235969423
Principal investigator 1 Organon Llc $472.80 09/22/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
3475-716 No dispute reported 06/30/2026 1173042232
Principal investigator 1 Merck Sharp & Dohme LLC $99,630.72 08/31/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator Controlled Clinical study of Adjuvant V940 mRNA-4157 Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma INTerpath-001 No dispute reported 06/30/2026 1232937426
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,750.00 08/07/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139327
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,591.83 08/07/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139329
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $80,571.24 08/07/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139331
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,750.00 08/07/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139333
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,791.78 08/07/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139335
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $131,857.74 08/07/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139337
Recipient Regeneron Pharmaceuticals, Inc. $2,629.59 08/05/2025 Covered Recipient Physician A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184120509
Recipient PFIZER INC. $3,200.00 08/01/2025 Covered Recipient Physician ONTORPACEPT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726282
Recipient PFIZER INC. $3,200.00 08/01/2025 Covered Recipient Physician ONTORPACEPT CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228727865
Principal investigator 2 Merck Sharp & Dohme LLC $15,626.00 07/18/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1232925563
Principal investigator 1 TAIHO ONCOLOGY, INC. $4,500.00 04/22/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors No dispute reported 06/30/2026 1211415371
Principal investigator 1 TAIHO ONCOLOGY, INC. $550.00 04/22/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors No dispute reported 06/30/2026 1211415373
Principal investigator 1 TAIHO ONCOLOGY, INC. $20,023.00 04/22/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors No dispute reported 06/30/2026 1211416792
Principal investigator 1 TAIHO ONCOLOGY, INC. $550.00 04/22/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors No dispute reported 06/30/2026 1211418203
Principal investigator 1 TAIHO ONCOLOGY, INC. $2,683.00 04/22/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors No dispute reported 06/30/2026 1211420359
Principal investigator 1 TAIHO ONCOLOGY, INC. $550.00 04/22/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors No dispute reported 06/30/2026 1211420361
Principal investigator 1 Merck Sharp & Dohme LLC $8,325.12 04/16/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab MK-3475 versus placebo after complete resection of high-risk Stage III melanoma# A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group No dispute reported 06/30/2026 1232925141
Principal investigator 1 Incyte Corporation $3,000.00 04/09/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491292
Principal investigator 1 Incyte Corporation $1,950.00 04/09/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491298
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $827.58 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139239
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,450.00 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139243
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,512.00 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139245
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $918.54 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139247
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,301.76 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139249
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139251
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $300.00 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139253
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,888.74 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139255
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139257
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,204.56 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139259
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,500.00 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $161.28 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139263
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $302.40 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139265
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $540.54 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139267
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139269
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $370.44 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,839.72 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,631.44 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,800.00 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,727.20 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $156.24 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139283
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,659.86 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,969.88 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139287
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $100.00 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139289
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,357.02 04/09/2025 Covered Recipient Teaching Hospital
UNIVERSITY OF IOWA HOSP & CLINICS
A RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROL, PHASE 2/3 STUDY OF FIRST-LINE INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB COMPARED TO NIVOLUMAB MONOTHERAPY IN SUBJECTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184139291
Recipient Regeneron Pharmaceuticals, Inc. $443.22 04/05/2025 Covered Recipient Physician A MULTICENTER, OPEN-LABEL, PHASE 2 STUDY OF INTRATUMORAL CMP-001 IN COMBINATION WITH INTRAVENOUS NIVOLUMAB IN SUBJECTS WITH REFRACTORY UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184120507
Principal investigator 1 Incyte Corporation $59.00 04/02/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491220
Principal investigator 1 Incyte Corporation $780.00 04/02/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491226
Principal investigator 1 Incyte Corporation $5,337.00 04/02/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491232
Principal investigator 1 Incyte Corporation $866.00 04/02/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491239
Principal investigator 1 Incyte Corporation $488.00 04/02/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491245
Principal investigator 1 Incyte Corporation $638.00 04/02/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491250
Principal investigator 1 Incyte Corporation $489.00 04/02/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491256
Principal investigator 1 Incyte Corporation $725.00 04/02/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491263
Principal investigator 1 Incyte Corporation $6,750.00 04/02/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491269
Principal investigator 1 Incyte Corporation $507.00 04/02/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491274
Principal investigator 1 Incyte Corporation $5,940.00 04/02/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491281
Principal investigator 1 Incyte Corporation $2,500.00 04/02/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491287
Principal investigator 1 Incyte Corporation $1,300.00 04/02/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491304
Principal investigator 1 Incyte Corporation $1,500.00 04/02/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491311
Principal investigator 1 Incyte Corporation $5,337.00 04/02/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491317
Principal investigator 1 Incyte Corporation $2,500.00 04/02/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491323
Principal investigator 1 TAIHO ONCOLOGY, INC. $1,000.00 02/05/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors No dispute reported 06/30/2026 1211415367
Principal investigator 1 TAIHO ONCOLOGY, INC. $550.00 02/05/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors No dispute reported 06/30/2026 1211415369
Principal investigator 1 TAIHO ONCOLOGY, INC. $550.00 02/05/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors No dispute reported 06/30/2026 1211416790
Principal investigator 1 TAIHO ONCOLOGY, INC. $550.00 02/05/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors No dispute reported 06/30/2026 1211417469
Principal investigator 1 TAIHO ONCOLOGY, INC. $550.00 02/05/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors No dispute reported 06/30/2026 1211418199
Principal investigator 1 TAIHO ONCOLOGY, INC. $550.00 02/05/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors No dispute reported 06/30/2026 1211418201
Principal investigator 1 TAIHO ONCOLOGY, INC. $550.00 02/05/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors No dispute reported 06/30/2026 1211418897
Principal investigator 1 TAIHO ONCOLOGY, INC. $550.00 02/05/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors No dispute reported 06/30/2026 1211419621
Principal investigator 1 TAIHO ONCOLOGY, INC. $550.00 02/05/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors No dispute reported 06/30/2026 1211420355
Principal investigator 1 TAIHO ONCOLOGY, INC. $550.00 02/05/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
Phase 1/2 Open-Label Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX295 in Subjects With Wild-Type TP53 Advanced Solid Tumors No dispute reported 06/30/2026 1211420357
Principal investigator 1 Incyte Corporation $7,800.00 01/06/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491203
Principal investigator 1 Incyte Corporation $1,460.00 01/06/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491209
Principal investigator 1 Incyte Corporation $1,500.00 01/06/2025 Covered Recipient Teaching Hospital
University Of Iowa Hosp & Clinics
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) No dispute reported 06/30/2026 1240491215